Page 1 | Search Results | The Hematologist | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Articles

Battle of the Clones: Somatic Genetic Rescue of Pediatric Patients With MDS Teaches Us About MDS Biology in 2021 and a Platform for the Future

Amy DeZern, MD, MHS

The Hematologist (2022) 19 (1)

https://doi.org/10.1182/hem.V19.1.202214

Published: 2022

Articles

Older Patients With High-Risk MDS Benefit From Allogeneic Stem Cell Transplantation

Michael J. Hochman, MD, Amy DeZern, MD, MHS

The Hematologist (2021) 18 (6)

https://doi.org/10.1182/hem.V18.6.202161

Published: 2021

Articles

Release More Inhibitions? Pegcetacoplan Treatment for Patients With Paroxysmal Nocturnal Hemoglobinuria

Gloria F. Gerber, MD, Amy Dezern, MD, MHS

The Hematologist (2021) 18 (5)

https://doi.org/10.1182/hem.V18.5.202151

Published: 2021

Articles

Can We “Go with the Flow?”

Amanda B. Kagan, MD, Amy DeZern, MD, MHS

The Hematologist (2021) 18 (3)

Published: 2021

Articles

Short-term Gain But Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors

Amy DeZern, MD, MHS

The Hematologist (2021) 18 (2)

Published: 2021

Articles

Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers

Amy DeZern, MD, MHS

The Hematologist (2020) 18 (1)

Published: 2020

Articles

Safe Tension: What the Latest Data Say About Waiting to Induce in AML

Amy DeZern, MD, MHS

The Hematologist (2020) 17 (6)

Published: 2020

Articles

Variant CURation: A Key Clinical Need Toward CURes in Patients With Inherited Predisposition

Amy DeZern, MD, MHS

The Hematologist (2020) 17 (5)

Published: 2020

Articles

CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations

Alexander Ambinder, MD, MPH, Amy DeZern, MD, MHS

The Hematologist (2020) 17 (4)

https://doi.org/10.1182/hem.V17.4.12884901909

Published: 2020

Articles

Can Leuk-warm Be Hot? Heating Up the Debate of Non-canonical Hotspot Spliceosomal Mutations in Myeloid Pathogenesis

Amy DeZern, MD, MHS, Andrew H. Marple, MD, PhD

The Hematologist (2020) 17 (3)

https://doi.org/10.1182/hem.V17.3.10321

Published: 2020

Articles

Identification of Malignant Cell Populations Years Before Development of Treatment-related Leukemia in Patients With Myeloma

Amy DeZern, MD, MHS

The Hematologist (2020) 17 (2)

https://doi.org/10.1182/hem.V17.2.10253

Published: 2020

Articles

2019 Brings Biologic Understanding and Hope for Patients With TP53 Mutated Myelodysplastic Syndrome

Amy DeZern, MD, MHS, Theodoros Karantanos, MD, PhD

The Hematologist (2019) 17 (1)

https://doi.org/10.1182/hem.V17.1.10133

Published: 2019

Articles

Does Your MDS Treatment Have Mettle? The Utility of Iron Chelation Is Always a Point of Discussion in MDS

Amy DeZern, MD, MHS

The Hematologist (2019) 16 (6)

https://doi.org/10.1182/hem.V16.6.9910

Published: 2019

Articles

Compelling Evidence for Targeted Immunotherapy As Treatment for AML

Amanda B. Kagan, MD, Amy DeZern, MD, MHS

The Hematologist (2019) 16 (5)

Published: 2019

Articles

Compelling Evidence for Targeted Immunotherapy As Treatment for AML

Amy DeZern, MD, MHS

The Hematologist (2019) 16 (5)

https://doi.org/10.1182/hem.V16.5.9779

Published: 2019

Articles

Should We Utilize Maintenance Therapy Post-Hematopoietic Cell Transplantation in Patients With FLT3/ITD-positive AML?

Amy DeZern, MD, MHS

The Hematologist (2019) 16 (4)

https://doi.org/10.1182/hem.V16.4.9638

Published: 2019

Articles

Thrombocytopenia Post-transplantation: A Clinical Challenge in Need of a Therapy

Amy DeZern, MD, MHS

The Hematologist (2019) 16 (3)

https://doi.org/10.1182/hem.V16.3.9512

Published: 2019

Articles

A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients

Amy DeZern, MD, MHS

The Hematologist (2019) 16 (2)

https://doi.org/10.1182/hem.V16.2.9382

Published: 2019

NARROW

Battle of the Clones: Somatic Genetic Rescue of Pediatric Patients With MDS Teaches Us About MDS Biology in 2021 and a Platform for the Future

Older Patients With High-Risk MDS Benefit From Allogeneic Stem Cell Transplantation

Release More Inhibitions? Pegcetacoplan Treatment for Patients With Paroxysmal Nocturnal Hemoglobinuria

Can We “Go with the Flow?”

Short-term Gain But Long-term Pain? Clonal Hematopoiesis and the Risk of Therapy-related Myeloid Neoplasms After Treatment for Solid Tumors

Big Questions in 2020: Single-cell Sequencing in Myeloid Malignancies Brings Us Closer to Answers

Safe Tension: What the Latest Data Say About Waiting to Induce in AML

Variant CURation: A Key Clinical Need Toward CURes in Patients With Inherited Predisposition

CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations

Can Leuk-warm Be Hot? Heating Up the Debate of Non-canonical Hotspot Spliceosomal Mutations in Myeloid Pathogenesis

Identification of Malignant Cell Populations Years Before Development of Treatment-related Leukemia in Patients With Myeloma

2019 Brings Biologic Understanding and Hope for Patients With TP53 Mutated Myelodysplastic Syndrome

Does Your MDS Treatment Have Mettle? The Utility of Iron Chelation Is Always a Point of Discussion in MDS

Compelling Evidence for Targeted Immunotherapy As Treatment for AML

Compelling Evidence for Targeted Immunotherapy As Treatment for AML

Should We Utilize Maintenance Therapy Post-Hematopoietic Cell Transplantation in Patients With FLT3/ITD-positive AML?

Thrombocytopenia Post-transplantation: A Clinical Challenge in Need of a Therapy

A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only